Flagship Biosciences to present at the premier toxicologic pathology conference in Japan
Boulder, CO – January 23, 2010 – Flagship Biosciences LLC,(Flagship) will present at a Digital Pathology Session at the 26th Annual meeting of the Japanese Society of Toxicologic Pathology, Japan’s premier organization for the application of toxicologic pathology in human health. Dr. David Young, DVM, DACVP, DABT, President and Chief Pathologist at Flagship will present a session on the general use of digital pathology in pharmceutical drug development with an emphasis in xenograft models in oncology drug development. “It is exciting to interact with my colleagues in Japan, and to exchange ideas with them on utilizing whole slide imaging for making more quantitative assessment of efficacy and toxicity. Digital pathology is designed to eliminate geographic barriers, so this is a timely meeting. Flagship was created to educate pathologists in the utility and applications of digital pathology to further its use and growth on a global scale. ” This is the second year that a pathologist from Flagship Biosciences has presented at the JSTP annual meeting. The presentation is titled Digital Pathology with Xenografts in Drug Development.
Flagship Biosciences is a pathologist-owned company focused on utilizing whole slide imaging for quantitative pathology in pharmaceutical and device applications.
